Research programme: prostate cancer therapy - Berg Pharma/CPDR/HJF

Drug Profile

Research programme: prostate cancer therapy - Berg Pharma/CPDR/HJF

Latest Information Update: 21 Aug 2013

Price : $50

At a glance

  • Originator Berg Pharma; Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Prostate cancer

Most Recent Events

  • 09 Aug 2013 Early research in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top